Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 8/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29695801 | 1.00 | P2RY12 (0.39) | P2RY12RXFP1ADORA3P2RY2PI4KA | |
| SCHEMBL22133776 | 0.90 | TRPM2 (0.44) | RXFP1 | |
| SCHEMBL29695843 | 0.90 | DOT1L (0.42) | P2RY12RXFP1ADORA3P2RY2PI4KA | |
| SCHEMBL12379229 | 0.86 | P2RY12 (0.44) | P2RY12P2RY2 | |
| SCHEMBL24450929 | 0.83 | RXFP1 (0.49) | P2RY12RXFP1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29695854 | 0.83 | RXFP1 (0.49) | P2RY12RXFP1PI4KAPI4K2BPI4K2A | |
| SCHEMBL14005602 | 0.79 | P2RY12 (0.43) | P2RY12 | |
| SCHEMBL14005604 | 0.79 | P2RY12 (0.44) | P2RY12ADORA3 | |
| SCHEMBL22837891 | 0.78 | RXFP1 (0.51) | RXFP1 | |
| SCHEMBL12379185 | 0.78 | RXFP1 (0.39) | P2RY12RXFP1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-26 | — | — | US | disclosed |
| WO-2020132603-A2 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ADSL, SLC35B2, ADORA1 | P2RY12 312/4885RXFP1 3582/4885ADORA3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.